{"Clinical Trial ID": "NCT00096356", "Intervention": ["INTERVENTION 1:", "1st arm - CoQ10 and vitamin E", "CoQ10 100mg capsule combined with vitamin E 100 IU taken orally three times a day.", "INTERVENTION 2:", "2 arms - Placebo and vitamin E", "Placebo-vitamin E 100 mg/day in 3 doses"], "Eligibility": ["Incorporation criteria:", "Signed consent", "Hg > 11g/dl; supportive measures (erythropoietin, transfusion, iron therapy) should be used to help maintain Hgb levels", "Total Cholesterol > 160 mg/dL.", "Women with primary diagnosis of cancer (arms)", "\u2022 Anticipated adjuvant chemotherapy (neoadjuvant chemotherapy is excluded)", "PSC > 60", "Bilirubine < 1.5 x ULN", "- SGOT < 2.5 x LSN", "- SGPT < 2.5 x LSN", "- Exclusion criteria:", "Recent involuntary weight loss (> 5% of body weight in the last 3 months)", "The statin therapy - current or planned during the study. Below is a list of some statin medications commonly used. (Note: This guide is useful, not a complete list.)", "Atorvastatin (Lipitor)", "Cerivastatin", "- Fluvastatin (Lescol)", "- Lovastatin (Mevacor, Altocor, Advicor)", "- Mevastatin", "- Pravastatin (Pravachol)", "Rosuvastatin", "- Simvastatin (Zocor)", "Current or planned use of the following fatigue medications", "- Corticosteroids (intermittent use in chemotherapy is allowed)", "Amphetamines or other stimulants, including methylphenidate (Ritaline) or modafinil (Provigil)", "Patients diagnosed with uncontrolled hypertension", "\u2022 Male breast cancer patients", "\u2022 Pregnant women are excluded from participating in this study; a serum pregnancy test is required within one week of registration if the patient is a woman of childbearing age.", "Anticoagulant treatment - current or planned during study (except for the maintenance of the catheter patent)", "Patients with uncontrolled thyroid dysfunction"], "Results": ["Performance measures:", "Effects of coenzyme Q10 on fatigue (measured by POMS-F) 24 weeks after randomisation", "POMS-F is the Pattern of mood states - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue.", "Duration: 24 weeks", "Results 1:", "Arm/group title: arms 1 - CoQ10 and vitamin E", "Description of the arm/group: CoQ10 100mg capsule combined with vitamin E 100 IU taken orally three times a day.", "Total number of participants analysed: 122", "Average of least squares (standard error)", "Unit of measurement: units on a scale 6.96 (0.71)", "Results 2:", "Title of the arm/group: arms 2 - Placebo and vitamin E", "Description of the arm/group: Placebo-vitamin E 100 mg/day in 3 doses", "Total number of participants analysed: 114", "Average of least squares (standard error)", "Unit of measurement: units on a scale 8.33 (0.79)"], "Adverse Events": ["Undesirable Events 1:", "Total: 22/100 (22.0%)", "ANC 11/100 (11.00 %)", "WBC 4/100 (4.0%)", "1/100 anemia (1.0%)", "Hypotension 1/100 (1.0%)", "- L vent sy d 0/100 (0.00 %)", "Chest pain 0/100 (0.00 %)", "Constipation 1/100 (1.0%)", "Diarrhoea 3/100 (3.0 per cent)", "Ileus 1/100 (1.00%)", "Vomiting 1/100 (1.0%)", "Abd pain 0/100 (0.00 %)", "Nausea 1/100 (1.0%)", "1/100 (1.0%) allergic reaction", "1/100 (1.00%) fatigue", "Adverse Events 2:", "Total: 15/93 (16.13 per cent)", "ANC 4/93 (4.30%)", "WBC 2/93 (2.15 per cent)", "Anemia 0.93 (0.00 %)", "Hypotension 0.93 (0.00 %)", "- L vent sy d 1/93 (1.08%)", "Chest pain 1/93 (1.08%)", "Constipation 1/93 (1.08%)", "Diarrhoea 2/93 (2.15 per cent)", "Ileus 0.93 (0.00 %)", "Vomiting 1/93 (1.08%)", "Abd 1/93 pain (1.08%)", "Nausea 3/93 (3.23%)", "- Allergic reaction 0/93 (0.00 %)", "3/93 (3.23%)", "Fever 1/93 (1.08%)"]}